Collaborative Editor
SC
JP
AI
+1
4 suggestions
Sections
References (4)
[1] Valles-Colomer, M. et al. (2019). The neuroactive potential ...
[2] Zheng, P. et al. (2016). Gut microbiome remodeling induces d...
[3] Kelly, J.R. et al. (2019). Transferring the blues: Depressio...
[4] Jiang, H. et al. (2015). Altered fecal microbiota compositio...
Dr. Sarah Chen,Dr. James Park,Dr. Maria Santos
Abstract
Treatment-resistant depression (TRD) affects approximately 30% of patients with major depressive disorder. Recent evidence suggests that the gut-brain axis plays a crucial role in modulating mood and cognitive function through microbial metabolite signaling. This study employs a multi-omics approach combining 16S rRNA sequencing, metabolomics, and proteomics to identify novel biomarkers associated with TRD.
Introduction
Major depressive disorder (MDD) is a leading cause of disability worldwide, affecting over 280 million people globally. While conventional antidepressants are effective for many patients, approximately 30% develop treatment-resistant depression (TRD), defined as failure to respond to two or more adequate antidepressant trials.
Emerging evidence from the past decade has established a bidirectional communication pathway between the gut microbiome and the central nervous system, termed the gut-brain axis. This axis involves neural, endocrine, immune, and metabolic signaling pathways that can influence mood, cognition, and behavior.
JP
Dr. James Park is editing
Methods
We enrolled 847 participants across three clinical sites: Stanford Medicine, Johns Hopkins, and Cleveland Clinic. Participants were stratified into three groups: TRD patients (n=312), treatment-responsive MDD patients (n=289), and healthy controls (n=246).
Fecal samples were collected at baseline and at 8-week follow-up. 16S rRNA gene sequencing was performed using the Illumina MiSeq platform targeting the V3-V4 region. Metabolomic profiling was conducted using LC-MS/MS, and proteomic analysis utilized TMT-labeled quantitative mass spectrometry.
Results
Our analysis revealed significant differences in gut microbiome composition between TRD patients and both control groups. Specifically, TRD patients showed:
• Reduced abundance of Faecalibacterium prausnitzii (p < 0.001)
• Elevated levels of Eggerthella lenta (p < 0.01)
• Decreased short-chain fatty acid (SCFA) production, particularly butyrate
• Altered tryptophan metabolism with increased kynurenine pathway activation
The multi-omics integration identified a panel of 14 biomarkers that predicted TRD status with 87% accuracy (AUC = 0.91, 95% CI: 0.88-0.94).
Discussion
These findings provide compelling evidence for a distinct gut microbiome signature in treatment-resistant depression. The identified biomarker panel offers potential clinical utility for early identification of patients at risk for treatment resistance, enabling more targeted therapeutic interventions.
The reduction in butyrate-producing bacteria, particularly F. prausnitzii, is consistent with previous reports linking SCFA deficiency to neuroinflammation and blood-brain barrier dysfunction. Our novel finding of elevated kynurenine pathway metabolites in TRD patients suggests a mechanistic link between gut microbial metabolism and central serotonergic dysfunction.
Chen
Park
Council
Collaborative Editor
SC
JP
AI
+1
4 suggestions
Sections
References (4)
[1] Valles-Colomer, M. et al. (2019). The neuroactive potential ...
[2] Zheng, P. et al. (2016). Gut microbiome remodeling induces d...
[3] Kelly, J.R. et al. (2019). Transferring the blues: Depressio...
[4] Jiang, H. et al. (2015). Altered fecal microbiota compositio...
Dr. Sarah Chen,Dr. James Park,Dr. Maria Santos
Abstract
Treatment-resistant depression (TRD) affects approximately 30% of patients with major depressive disorder. Recent evidence suggests that the gut-brain axis plays a crucial role in modulating mood and cognitive function through microbial metabolite signaling. This study employs a multi-omics approach combining 16S rRNA sequencing, metabolomics, and proteomics to identify novel biomarkers associated with TRD.
Introduction
Major depressive disorder (MDD) is a leading cause of disability worldwide, affecting over 280 million people globally. While conventional antidepressants are effective for many patients, approximately 30% develop treatment-resistant depression (TRD), defined as failure to respond to two or more adequate antidepressant trials.
Emerging evidence from the past decade has established a bidirectional communication pathway between the gut microbiome and the central nervous system, termed the gut-brain axis. This axis involves neural, endocrine, immune, and metabolic signaling pathways that can influence mood, cognition, and behavior.
JP
Dr. James Park is editing
Methods
We enrolled 847 participants across three clinical sites: Stanford Medicine, Johns Hopkins, and Cleveland Clinic. Participants were stratified into three groups: TRD patients (n=312), treatment-responsive MDD patients (n=289), and healthy controls (n=246).
Fecal samples were collected at baseline and at 8-week follow-up. 16S rRNA gene sequencing was performed using the Illumina MiSeq platform targeting the V3-V4 region. Metabolomic profiling was conducted using LC-MS/MS, and proteomic analysis utilized TMT-labeled quantitative mass spectrometry.
Results
Our analysis revealed significant differences in gut microbiome composition between TRD patients and both control groups. Specifically, TRD patients showed:
• Reduced abundance of Faecalibacterium prausnitzii (p < 0.001)
• Elevated levels of Eggerthella lenta (p < 0.01)
• Decreased short-chain fatty acid (SCFA) production, particularly butyrate
• Altered tryptophan metabolism with increased kynurenine pathway activation
The multi-omics integration identified a panel of 14 biomarkers that predicted TRD status with 87% accuracy (AUC = 0.91, 95% CI: 0.88-0.94).
Discussion
These findings provide compelling evidence for a distinct gut microbiome signature in treatment-resistant depression. The identified biomarker panel offers potential clinical utility for early identification of patients at risk for treatment resistance, enabling more targeted therapeutic interventions.
The reduction in butyrate-producing bacteria, particularly F. prausnitzii, is consistent with previous reports linking SCFA deficiency to neuroinflammation and blood-brain barrier dysfunction. Our novel finding of elevated kynurenine pathway metabolites in TRD patients suggests a mechanistic link between gut microbial metabolism and central serotonergic dysfunction.
Chen
Park
Council